USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Volume: 7, Issue: 10, Pages: 1580 - 1590
Published: Oct 1, 2019
Abstract
PD-1 (CD279)-PD-L1 (CD274) inhibitory signaling is critical for cancer immune evasion, and thus has become one of the major targets in anticancer immunotherapy. There are several studies that demonstrate the potent effects of posttranslational modifications of CD274 on immune inactivation and suppression, such as ubiquitination, phosphorylation, glycosylation, and palmitoylation. However, the regulatory mechanisms for CD274 deubiquitination are...
Paper Details
Title
USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Published Date
Oct 1, 2019
Volume
7
Issue
10
Pages
1580 - 1590
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.